To effectively fight against the human immunodeficiency virus infection/ acquired immunodeficiency syndrome (HIV/AIDS) epidemic, ongoing development of novel HIV protease inhibitors is required. Inexpensive high-throughput screening assays are needed to quickly scan large sets of chemicals for potential inhibitors. We have developed a F？rster resonance energy transfer (FRET)-based, HIV protease-sensitive sensor using a combination of a fluorescent protein pair, namely mCerulean and mCitrine. Through extensive in vitro characterization, we show that the FRET-HIV sensor can be used in HIV protease screening assays. Furthermore, we have used the FRET-HIV sensor for intracellular quantitative detection of HIV protease activity in living cells, which more closely resembles an actual viral infection than an in vitro assay. We have developed a high-throughput method that employs a ratiometric flow cytometry for analyzing large populations of cells that express the FRET-HIV sensor. The method enables FRET measurement of single cells with high sensitivity and speed and should be used when subpopulation-specific intracellular activity of HIV protease needs to be estimated. In addition, we have used a confocal microscopy sensitized emission FRET technique to evaluate the usefulness of the FRET-HIV sensor for spatiotemporal detection of intracellular HIV protease activity.
References
[1]
Demberg, T.; Robert-Guroff, M. Controlling the HIV/AIDS epidemic: Current status and global challenges. Front. Immunol. 2012, 3, 250, doi:10.3389/fimmu.2012.00250.
[2]
Wensing, A.M.J.; van Maarseveen, N.M.; Nijhuis, M. Fifteen years of HIV Protease Inhibitors: Raising the barrier to resistance. Antivir. Res. 2010, 85, 59–74.
[3]
Perno, C.F.; Newcomb, F.M.; Davis, D.A.; Aquaro, S.; Humphrey, R.W.; Caliò, R.; Yarchoan, R. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J. Infect. Dis. 1998, 178, 413–422.
[4]
Bulgheroni, E.; Citterio, P.; Croce, F.; Lo Cicero, M.; Viganò, O.; Soster, F.; Chou, T.-C.; Galli, M.; Rusconi, S. Analysis of protease inhibitor combinations in vitro: Activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. J. Antimicrob. Chemother. 2004, 53, 464–468.
[5]
Salomon, H.; Belmonte, A.; Nguyen, K.; Gu, Z.; Gelfand, M.; Wainberg, M. A Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1. J. Clin. Microbiol. 1994, 32, 2000–2002.
[6]
Mulato, A.S.; Cherrington, J.M. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: In vitro analyses. Antivir. Res. 1997, 36, 91–97.
[7]
Lü, J.-M.; Yan, S.; Jamaluddin, S.; Weakley, S.M.; Liang, Z.; Siwak, E.B.; Yao, Q.; Chen, C. Ginkgolic acid inhibits HIV protease activity and HIV infection in vitro. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2012, 18, 293–298.
[8]
Gershkovich, A.A.; Kholodovych, V.V. Fluorogenic substrates for proteases based on intramolecular fluorescence energy transfer (IFETS). J. Biochem. Biophys. Methods 1996, 33, 135–162.
[9]
Hu, K.; Clément, J.-F.; Abrahamyan, L.; Strebel, K.; Bouvier, M.; Kleiman, L.; Mouland, A.J. A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer. J. Virol. Methods 2005, 128, 93–103.
[10]
Jin, S.; Ellis, E.; Veetil, J.V.; Yao, H.; Ye, K. Visualization of human immunodeficiency virus protease inhibition using a novel F？rster resonance energy transfer molecular probe. Biotechnol. Prog. 2011, 27, 1107–1114.
[11]
Yao, H.; Jin, S. Enhancement of probe signal for screening of HIV-1 protease inhibitors in living cells. Sensors 2012, 12, 16759–16770.
[12]
C？té, H.C.; Brumme, Z.L.; Harrigan, P.R. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 2001, 75, 589–594.
[13]
Shetty, R.P.; Endy, D.; Knight, T.F. Engineering BioBrick vectors from BioBrick parts. J. Biol. Eng. 2008, 2, 5.
[14]
Millington, M.; Grindlay, G.J.; Altenbach, K.; Neely, R.K.; Kolch, W.; Bencina, M.; Read, N.D.; Jones, A.C.; Dryden, D.T.F.; Magennis, S.W. High-precision FLIM-FRET in fixed and living cells reveals heterogeneity in a simple CFP-YFP fusion protein. Biophys. Chem. 2007, 127, 155–164.
[15]
He, J.; Choe, S.; Walker, R.; Di Marzio, P.; Morgan, D.O.; Landau, N.R. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 1995, 69, 6705–6711.
[16]
Connor, R.I.; Chen, B.K.; Choe, S.; Landau, N.R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995, 206, 935–944.
[17]
Feige, J.N.; Sage, D.; Wahli, W.; Desvergne, B.; Gelman, L. PixFRET, an ImageJ plug-in for FRET calculation that can accommodate variations in spectral bleed-throughs. Microsc. Res. Tech. 2005, 68, 51–58.
[18]
Wu, X.; Simone, J.; Hewgill, D.; Siegel, R.; Lipsky, P.E.; He, L. Measurement of two caspase activities simultaneously in living cells by a novel dual FRET fluorescent indicator probe. Cytom. Part A J. Int. Soc. Anal. Cytol. 2006, 69, 477–486.
[19]
Davis, D.A.; Newcomb, F.M.; Starke, D.W.; Ott, D.E.; Mieyal, J.J.; Yarchoan, R. Thioltransferase (glutaredoxin) is detected within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease in vitro. J. Biol. Chem. 1997, 272, 25935–25940.
[20]
Shaner, N.C.; Steinbach, P.A.; Tsien, R.Y. A guide to choosing fluorescent proteins. Nat. Methods 2005, 2, 905–909.
[21]
Müller, S.M.; Galliardt, H.; Schneider, J.; Barisas, B.G.; Seidel, T. Quantification of F？rster resonance energy transfer by monitoring sensitized emission in living plant cells. Front. Plant Sci. 2013, 4, 413, doi:10.3389/fpls.2013.00413.
